MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Zoetis Inc

Chiusa

SettoreSettore sanitario

159.56 -2.43

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

159.31

Massimo

166.05

Metriche Chiave

By Trading Economics

Entrata

-101M

581M

Vendite

-83M

2.3B

P/E

Media del settore

30.101

63.778

EPS

1.4

Rendimento da dividendi

1.21

Margine di Profitto

25.076

Dipendenti

13,800

EBITDA

-133M

906M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+27.04% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.21%

2.39%

Utili prossimi

6 mag 2025

Prossima data del' Ex Dividendo

21 apr 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-5.1B

74B

Apertura precedente

161.99

Chiusura precedente

159.56

Notizie sul Sentiment di mercato

By Acuity

29%

71%

87 / 386 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Zoetis Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 nov 2024, 12:47 UTC

Utili

Zoetis Lifts Guidance On Strong Demand as 3Q Beats Market Views

6 ago 2024, 11:52 UTC

Utili

Zoetis Raises Guidance After 2Q Sales, Earnings Rise

20 feb 2025, 08:00 UTC

Notizie principali

A Bird-Flu Vaccine Could Bring Down Egg Prices. Why the Poultry Industry Is Fighting It. -- Barrons.com

13 feb 2025, 13:47 UTC

Utili

Zoetis Plunges 9% As 2025 Guidance Misses Expectations -- IBD

13 feb 2025, 12:09 UTC

Utili

Zoetis Sees FY25 Adj EPS $6-Adj EPS $6.10 >ZTS

13 feb 2025, 12:08 UTC

Utili

Zoetis Sees FY25 Rev $9.225B-$9.375B >ZTS

13 feb 2025, 12:08 UTC

Utili

Zoetis Sees FY25 EPS $5.70-EPS $5.80 >ZTS

13 feb 2025, 12:00 UTC

Utili

Zoetis 4Q EPS $1.29 >ZTS

13 feb 2025, 12:00 UTC

Utili

Zoetis 4Q Rev $2.32B >ZTS

13 feb 2025, 12:00 UTC

Utili

Zoetis 4Q Net $581M >ZTS

4 nov 2024, 14:05 UTC

Utili

Zoetis Barks Up A Third-Quarter Beat And Raise, But Stock Slips -- IBD

4 nov 2024, 12:06 UTC

Utili

Zoetis Sees 2024 Rev $9.2B-$9.3B >ZTS

4 nov 2024, 12:06 UTC

Utili

Zoetis Sees 2024 Adj EPS $5.86-Adj EPS $5.92 >ZTS

4 nov 2024, 12:05 UTC

Utili

Zoetis 3Q Adj EPS $1.58 >ZTS

4 nov 2024, 12:00 UTC

Utili

Zoetis 3Q Net $682M >ZTS

4 nov 2024, 12:00 UTC

Utili

Zoetis 3Q EPS $1.50 >ZTS

4 nov 2024, 12:00 UTC

Utili

Zoetis 3Q Rev $2.39B >ZTS

6 ago 2024, 11:44 UTC

Utili

Zoetis Earnings Growth Picks Up, Tops Views -- IBD

6 ago 2024, 11:09 UTC

Utili

Zoetis Raises 2024 Operational Revenue Growth View to 9%-11% >ZTS

6 ago 2024, 11:08 UTC

Utili

Zoetis Raises 2024 View To Adj EPS $5.78-Adj EPS $5.88 >ZTS

6 ago 2024, 11:08 UTC

Utili

Zoetis Raises 2024 View To Rev $9.1B-$9.25B >ZTS

6 ago 2024, 11:08 UTC

Utili

Zoetis 2Q Adj EPS $1.56 >ZTS

6 ago 2024, 11:00 UTC

Utili

Zoetis 2Q Net $624M >ZTS

6 ago 2024, 11:00 UTC

Utili

Zoetis 2Q Rev $2.36B >ZTS

6 ago 2024, 11:00 UTC

Utili

Zoetis 2Q EPS $1.37 >ZTS

2 mag 2024, 17:43 UTC

Utili

Zoetis Stock Climbs on Earnings Beat, but Worries Linger Over Key Medicine -- Barrons.com

2 mag 2024, 13:06 UTC

Utili

Zoetis Stock Climbs on Earnings Beat, but Worries Linger Over Key Medicine -- Barrons.com

2 mag 2024, 11:27 UTC

Utili

Zoetis Earnings Top; Pet Drugmaker Rises -- IBD

2 mag 2024, 11:00 UTC

Utili

Zoetis 1Q Net $599M >ZTS

2 mag 2024, 11:00 UTC

Utili

Zoetis 1Q EPS $1.31 >ZTS

Confronto tra pari

Modifica del prezzo

Zoetis Inc Previsione

Obiettivo di Prezzo

By TipRanks

27.04% in crescita

Previsioni per 12 mesi

Media 207.71 USD  27.04%

Alto 242 USD

Basso 180 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zoetis Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

7

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

162.8401 / 165.48Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Strong Bearish Evidence

Sentiment

By Acuity

87 / 386 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zoetis Inc

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.